Zentalis Pharmaceuticals (ZNTL) Other financing activities (2020 - 2026)

Zentalis Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $331000.0 for Q1 2026.

• On a quarterly basis, Other financing activities rose 75.13% year-over-year to $331000.0 in Q1 2026; TTM through Mar 2026 was $446000.0, a 53.79% increase from a year earlier, with the FY2025 full-year figure at $304000.0, down 12.89% from the prior year.
• Other financing activities advanced to $331000.0 in Q1 2026 per ZNTL's latest filing, from $115000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $1.3 million in Q1 2022 and bottomed at $9000.0 in Q2 2024.
• The 5-year median for Other financing activities is $309000.0 (2023), against an average of $440615.4.
• Across the five-year window, Other financing activities surged 495.57% in 2023 and sank 99.04% in 2024, its largest moves.
• Year by year, Other financing activities stood at $1.1 million in 2022, then plunged by 72.31% to $309000.0 in 2023, then slumped by 70.23% to $92000.0 in 2024, then grew by 25.0% to $115000.0 in 2025, then surged by 187.83% to $331000.0 in 2026.
• Per Business Quant, the three latest ZNTL Other financing activities figures stand at $331000.0 (Q1 2026), $115000.0 (Q3 2025), and $189000.0 (Q1 2025).